Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1

Conditions

Uterine Cervical Neoplasms 2Ovarian Neoplasms 2Ovarian Cancer Recurrent 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 18Cyclophosphamide 9fludarabine 8Nivolumab 8cemiplimab 5Carboplatin 5atezolizumab 4Gemcitabine 4Filgrastim 4Drug Therapy 4Docetaxel 4Cisplatin 4palbociclib 3durvalumab 3Paclitaxel 3Interleukin-2 3Bortezomib 3fludarabine phosphate 2epacadostat 2belinostat 2avelumab 2amminedichloro(2-methylpyridine)platinum(II) 2aldesleukin 2Tobacco Use Cessation Devices 2Temozolomide 2SS1(dsFv)PE38 2Riluzole 2Peripheral Blood Stem Cell Transplantation 2Oncolytic Virotherapy 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × disitamab vedotin × Gynecologic × Clear all
NCT06003231 2026-06-01

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Seagen Inc.

Phase 2 Active not recruiting
120 enrolled
GynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡